Aktuellt
SENASTE
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day. The presentations and discussions support our take on the company’s positive trajectory, and we reiterate our base case, suggesting a hefty upside from today’s levels. We believe the valuation gap will be closed next year on the back of increased sales, nearing profitability, further US progress and, hopefully, news related to its FDA regulatory processes. In addition, we expect more institutional interest to emerge, further fueling the positive share price momentum we have seen this year.
LÄS MER
